Primary Central Nervous System Lymphoma Clinical Trials

86 clinical trials for Primary Central Nervous System Lymphoma across international registries, including 25 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Tirabrutinib Maintenance Versus Placebo in Patients With Primary CNS Lymphoma in Complete Remission (JCOG2104) — RECRUITING · PHASE2
• Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL — RECRUITING · PHASE2
• A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) — RECRUITING · PHASE1
• Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma — RECRUITING · PHASE1
• A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies — RECRUITING · PHASE1
• A Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSL — RECRUITING · PHASE2
• Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma — RECRUITING · PHASE2
• A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies — RECRUITING · PHASE1
• Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas — RECRUITING · PHASE2
• Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL — RECRUITING · PHASE1
• Pembrolizumab, Ibrutinib and Rituximab in PCNSL — RECRUITING · PHASE1
• PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL. — RECRUITING · PHASE2
• Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma — RECRUITING
• Q702 for the Treatment of Patients With Hematologic Malignancies — RECRUITING · PHASE1
• Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL — RECRUITING · NA
• High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphoma — RECRUITING · PHASE2
• Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response — RECRUITING · PHASE2
• Rituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary Central Nervous System Lymphoma — RECRUITING · NA
• Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma — RECRUITING · PHASE2
• Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL — RECRUITING · NA
• Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients — RECRUITING · PHASE3
• Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL) — RECRUITING · PHASE2
• Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma — RECRUITING · PHASE2
• Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL — RECRUITING · PHASE2
• Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy — RECRUITING · PHASE2
• R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma — NOT_YET_RECRUITING · NA
• Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma — SUSPENDED · PHASE1
• A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants — COMPLETED · PHASE1
• Real-World Evidence of Effectiveness and Safety of Tirabrutinib in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: A Nationwide Study — COMPLETED
• The CAROLYN Trial: Lisocabtagene Maraleucel as First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients — TERMINATED · PHASE2
• Loc-R01: Randomized Phase IB/II Study of escalating doses of Lenalidomide and Ibrutinib in association with R-MPV as a targeted induction treatment for patients aged 18 to 60 (up to 65 for phase II) with a newly diagnosed Primary Central Nervous System Lymphoma — TERMINATED · PHASE2
• OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma — ACTIVE_NOT_RECRUITING · PHASE3
• Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• Methotrexate Early Toxicity Monitoring — NOT_YET_RECRUITING · NA
• Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL) — COMPLETED · PHASE1
• Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy — COMPLETED · PHASE2
• Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System Lymphoma — NOT_YET_RECRUITING · NA
• A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL) — ACTIVE_NOT_RECRUITING · PHASE1
• Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL — NOT_YET_RECRUITING · PHASE2
• New-diagnosed PCNSL Treated With Methotrexate (MTX) and Orelabrutinib-based Regimen — COMPLETED
• [18F]-Fludarabine PET/MRI in Primary Central Nervous System Lymphoma — COMPLETED · PHASE1
• Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL — ACTIVE_NOT_RECRUITING · PHASE1
• Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma. — ACTIVE_NOT_RECRUITING · PHASE1
• Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System — COMPLETED · PHASE2
• A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL — ACTIVE_NOT_RECRUITING · PHASE1
• High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ) — NOT_YET_RECRUITING · PHASE2
• First-line Treatment of PCNSL With the Combination of Orelabrutinib, Rituximab, and Methotrexate (ORM Regimen) — COMPLETED · PHASE2
• A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSL — OTHER · NA
• Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma — COMPLETED · PHASE1

Refine this search